Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv's Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $1.7 million for Q3 2025.

• Total Non-Current Liabilities for Q3 2025 came in at $1.7 million, changed N/A year-over-year; the trailing twelve-month figure through Jul 2025 was $1.7 million (changed N/A YoY), and the FY2024 annual result was $1.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities came in at $1.7 million for Q3 2025 at Pharma-Bio Serv, down from $1.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $8.9 million in Q1 2021 to a low of $1.7 million in Q3 2025.
• A 5-year average of $3.9 million and a median of $4.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 77.42% in 2021 and slumped 50.81% in 2022, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $5.0 million in 2021, then tumbled by 50.81% to $2.5 million in 2022, then advanced by 9.34% to $2.7 million in 2023, then fell by 28.6% to $1.9 million in 2024, then decreased by 13.42% to $1.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $1.7 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q4 2024), per Business Quant data.